Cover Image

Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction

Saved in:

Bibliographic Details
Main Authors:	Liyun Zhang (Author), Juan Chen (Author), Lianhua Yan (Author), Qin He (Author), Han Xie (Author), Manhua Chen (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
by: Liyun Zhang, et al.
Published: (2021)

Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023)

ATRIAL FIBRILLATION AND ARTERIAL HYPERTENSION: GENDER DIFFERENCES OF VENTRICULOATRIAL REMODELING WITH PRESERVED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2017)

Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol
by: Roland Gal, et al.
Published: (2020)

Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function
by: Thomas A. Mavrakanas, et al.
Published: (2019)

Cardiac Amyloidosis - An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction - Updated Diagnosis and Treatment Options
by: Roxana Cristina RIMBAS, et al.
Published: (2021)

Assessing cardiac contractility in hypertension with heart failure with preserved ejection fraction: the value of left ventricular strain
by: Simon W. Rabkin
Published: (2023)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024)

THE ROLE OF FACTORS AFFECTING THE FORMATION OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION
by: M. V. Kurkina, et al.
Published: (2017)

DIASTOLIC LEFT VENTRICULAR DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN ELDERLY
by: CALENICI Oleg, et al.
Published: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
by: Artem Ovchinnikov, et al.
Published: (2022)

Subclinical Hypothyroidism Predicted Adverse Cardiovascular Events in Patients with Ejection Fraction Preserved Heart Failure
by: Tan Q, et al.
Published: (2024)

Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis
by: Zhu Chen, et al.
Published: (2022)

Mitochondrial Reactive Oxygen Species Dysregulation in Heart Failure with Preserved Ejection Fraction: A Fraction of the Whole
by: Caroline Silveira Martinez, et al.
Published: (2024)

How to treat cardiac dyssynchrony in heart failure with reduced ejection fraction
by: Bogdan Stefan, et al.
Published: (2024)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction
by: Alexandrina Campos-Martins, et al.
Published: (2021)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022)

Association Between Hyperaldosteronemia and Electrophysiological Myocardial Activity in Heart Failure with Preserved Ejection Fraction
by: A. N. Shevelok
Published: (2020)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
by: Xiao Wang, et al.
Published: (2024)

Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction
by: Bogdan Ioan Coculescu, et al.
Published: (2018)

Features of structural and geometric remodeling of the heart and changes in the diastolic filling of the heart in patients with chronic heart failure of ischemic genesis with preserved left ventricular ejection fraction
by: V. A. Lysenko, et al.
Published: (2021)

Heart Failure with Preserved Ejection Fraction in a Postpartum Patient with Superimposed Preeclampsia and COVID-19
by: Rachel G. Sinkey, et al.
Published: (2020)

Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
by: Marlies Antlanger, et al.
Published: (2017)

Prognostic of NT-proBNP in heart failure patients with preserved, mid and reduced ejection fraction
by: Reynie Leonel Reinoso Gonella, et al.
Published: (2021)

Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction
by: Natasha Fillmore, et al.
Published: (2018)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023)

Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction
by: Z. M. Akhilgova, et al.
Published: (2020)

Evaluation of claims‐based computable phenotypes to identify heart failure patients with preserved ejection fraction
by: Sarah S. Cohen, et al.
Published: (2020)

Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms
by: Yujian Fan, et al.
Published: (2023)

A comprehensive evaluation of heart failure with preserved ejection fraction and the relationship to atrial fibrillation in Turkey
by: Muhammed Keskin
Published: (2020)

Prognostic Value of Inflammatory Cytokines in Predicting Hospital Readmissions in Heart Failure with Preserved Ejection Fraction
by: Zhao Z, et al.
Published: (2024)

Resistant Hypertension From Renal Artery Stenosis Leading to Heart Failure With Preserved Ejection Fraction
by: Motasem Alyamani MBBS, et al.
Published: (2018)

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023)

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS
by: O. M. Drapkina, et al.
Published: (2015)